SCHEMBL2447732

SCHEMBL2447732

CC(C)(C)N1CCN(c2ccc(F)nc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.39
DPP8 Q6V1X1 1/20 0.39
DPP9 Q86TI2 1/20 0.39
DPP7 Q9UHL4 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
CHRNB2 P17787 4/20 0.36
CHRNA4 P43681 4/20 0.36
DHFR P00374 2/20 0.36
HTR3A P46098 1/20 0.36
CHRM4 P08173 1/20 0.35
MAPT P10636 2/20 0.35
HSD11B1 P28845 2/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
NCOA1 Q15788 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NCOA3 Q9Y6Q9 1/20 0.35
MEN1 O00255 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17108483 0.80 GCK (0.45) CHRNB2CHRNA4DHFRHTR3AMAPT
SCHEMBL24540313 0.80 DHFR (0.42) CHRNB2CHRNA4DHFRHTR3AMAPT
SCHEMBL30477815 0.80 GCK (0.45) CHRNB2CHRNA4DHFRHTR3AMAPT
SCHEMBL24422281 0.80 MAPT (0.38) CHRNB2CHRNA4HTR3AMAPTHSD11B1
SCHEMBL1766217 0.80 ENPP2 (0.38) CHRNB2CHRNA4DHFRHTR3AMAPT
SCHEMBL27588061 0.77 GPR119 (0.39) DPP4DPP8DPP9DPP7DRD2
SCHEMBL16379150 0.77 MAPT (0.53) DPP4DPP8DPP9DPP7CHRNB2
SCHEMBL1709030 0.77 MAPT (0.57) MAPTHSD11B1LMNAHTTSMN1; SMN2
SCHEMBL18641228 0.76 AR (0.43) MAPTLMNAHTTNCOA1SMN1; SMN2
SCHEMBL4154350 0.75 CHRNB2 (0.43) DPP4DPP8DPP9DPP7DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530477-B2 Tropane urea derivatives, preparation thereof and therapeutic application thereof as modulators of the activity of 11betaHSD1 SANOFI (FR) 2013-09-10 US disclosed
EP-2364311-B1 TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 SANOFI SA (FR) 2013-07-03 EP disclosed
US-20110294809-A1 TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 SANOFI-AVENTIS (FR) 2011-12-01 US disclosed
EP-2364311-A1 TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 SANOFI (FR) 2011-09-14 EP disclosed
WO-2010049635-A1 TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 SANOFI-AVENTIS (FR) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294809-A1 TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 HSD11B1, HSD17B1, HSD17B11 DPP4 3203/4885DPP8 2904/4885DPP9 2965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.